MétaCan
Menu
Back to cohort
Record W2309442902 · doi:10.1016/j.jalz.2016.02.002

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

2016· review· en· W2309442902 on OpenAlexafffund
Bruno Dubois, Harald Hampel, Howard Feldman, Philip Scheltens, Paul Aisen, Sandrine Andrieu, Hovagim Bakardjian, Habib Benali, Lars Bertram, Kaj Blennow, Karl Broich, Enrica Cavedo, Sebastian J. Crutch, Jean‐François Dartigues, Charles Duyckaerts, Stéphane Epelbaum, Giovanni B. Frisoni, Serge Gauthier, Rémy Genthon, Alida A. Gouw, Marie‐Odile Habert, David M. Holtzman, Miia Kivipelto, Simone Lista, José Luís Molinuevo, Sid E. O’Bryant, Gil D. Rabinovici, Christopher C. Rowe, Stephen Salloway, Lon S. Schneider, Reisa A. Sperling, Marc Teichmann, María C. Carrillo, Jeffrey L. Cummings, Cliff R Jack

Bibliographic record

VenueAlzheimer s & Dementia · 2016
Typereview
Languageen
FieldMedicine
TopicDementia and Cognitive Impairment Research
Canadian institutionsDouglas Mental Health University InstituteUniversity of British Columbia
FundersJanssen PharmaceuticalsEngineering and Physical Sciences Research CouncilMcDonnell Center for Systems NeuroscienceUniversity of California, San DiegoGenentechNational Institutes of HealthNational Institute of General Medical SciencesH. Lundbeck A/SServierAvid RadiopharmaceuticalsUniversité Pierre et Marie CurieFujirebio EuropeVetenskapsrådetEisaiAgence Nationale de la RechercheEU Joint Programme – Neurodegenerative Disease ResearchNational Institute on AgingNational Institute for Health and Care ResearchCenter for Innovative MedicineNorthern California Institute for Research and EducationAssociation France ParkinsonDanoneFondation Brain CanadaLes Laboratories Pierre FabreAXA Research FundFondation pour l'Aide à la Recherche sur la Sclérose en PlaquesPfizerBiogenAstraZenecaEli Lilly and CompanyTau ConsortiumBristol-Myers SquibbSanofiEconomic and Social Research CouncilTauRx PharmaceuticalsCanadian Institutes of Health ResearchIpsenBundesinstitut für Arzneimittel und MedizinprodukteAlzheimer's AssociationFondation pour la Recherche sur AlzheimerMinistero della SaluteAmgenCalifornia Institute for Regenerative Medicine
KeywordsNatural historyDiseaseNatural (archaeology)MedicineHistoryPathologyInternal medicine

Abstract

fetched live from OpenAlex

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.005
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.006
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0050.005
Science and technology studies0.0000.002
Scholarly communication0.0020.002
Open science0.0020.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.100
GPT teacher head0.391
Teacher spread0.291 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1,904
Published2016
Admission routes2
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicDementia and Cognitive Impairment ResearchFrench-language works237,207